Riik: Euroopa Liit
keel: inglise
Allikas: EMA (European Medicines Agency)
anidulafungin
Pfizer Europe MA EEIG
J02AX06
anidulafungin
Antimycotics for systemic use
Candidiasis
Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years.
Revision: 26
Authorised
2007-09-20
25 B. PACKAGE LEAFLET 26 PACKAGE LEAFLET: INFORMATION FOR THE USER ECALTA 100 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION Anidulafungin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist or nurse. - If you or your child get any side effects, talk to your doctor, or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What ECALTA is and what it is used for 2. What you need to know before you or your child use ECALTA 3. How to use ECALTA 4. Possible side effects 5. How to store ECALTA 6. Contents of the pack and other information 1. WHAT ECALTA IS AND WHAT IT IS USED FOR ECALTA contains the active substance anidulafungin and is prescribed in adults and in paediatric patients aged 1 month to less than 18 years to treat a type of fungal infection of the blood or other internal organs called invasive candidiasis. The infection is caused by fungal cells (yeasts) called _Candida_. ECALTA belongs to a group of medicines called echinocandins. These medicines are used to treat serious fungal infections. ECALTA prevents normal development of fungal cell walls. In the presence of ECALTA, fungal cells have incomplete or defective cell walls, making them fragile or unable to grow. 2. WHAT YOU NEED TO KNOW BEFORE YOU OR YOUR CHILD USE ECALTA DO NOT USE ECALTA - if you are allergic to anidulafungin, other echinocandins (e.g. caspofungin acetate), or any of the other ingredients of this medicine (listed in section 6). WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist or nurse before using ECALTA. Your doctor may decide to monitor you - for liver function more closely if you develop liver problems during your treatment - if you are given anaesthetics during your treatment with ECALTA - for signs of an allergic reaction such as itching, Lugege kogu dokumenti
1 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT ECALTA 100 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 100 mg anidulafungin. The reconstituted solution contains 3.33 mg/mL anidulafungin and the diluted solution contains 0.77 mg/mL anidulafungin. Excipient with known effect: ECALTA contains 119 mg fructose in each vial. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. White to off-white solid. The reconstituted solution has a pH of 3.5 to 5.5. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years (see sections 4.4 and 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with ECALTA should be initiated by a physician experienced in the management of invasive fungal infections._ _ Posology Specimens for fungal culture should be obtained prior to therapy. Therapy may be initiated before culture results are known and can be adjusted accordingly once they are available. _Adult population (dosing and treatment duration) _ A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter. Duration of treatment should be based on the patient’s clinical response. In general, antifungal therapy should continue for at least 14 days after the last positive culture. _ _ There are insufficient data to support the 100 mg dose for longer than 35 days of treatment. _Patients with renal and hepatic impairment _ No dosing adjustments are required for patients with mild, moderate, or severe hepatic impairment. No dosing adjustments are required for patients with any degree of renal insufficiency, including those on dialysis. ECALTA can be given without regard to the timing of haemodialysis (see section 5.2). _Other special populations _ No dosing adjustments are required for adult pa Lugege kogu dokumenti